Having trouble accessing articles? Reset your cache.

FDA panel split on Meridia

FDA's Endocrinologic and Metabolic Drugs Advisory Committee split 8-8 on whether to withdraw anti-obesity drug Meridia sibutramine from Abbott Laboratories (NYSE:ABT) from the U.S.

Read the full 249 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE